GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 56.15B |
| Revenue (ttm) | 31.53B |
| Net Income (ttm) | 3.15B |
| Shares Out | 4.04B |
| EPS (ttm) | 0.76 |
| PE Ratio | 18.27 |
| Forward PE | 8.31 |
| Dividend | 0.61 (4.39%) |
| Ex-Dividend Date | May 15, 2025 |
| Volume | 4,945,142 |
| Average Volume | 8,514,170 |
| Open | 1,392.00 |
| Previous Close | 1,390.50 |
| Day's Range | 1,386.50 - 1,407.22 |
| 52-Week Range | 1,242.50 - 1,678.68 |
| Beta | 0.27 |
| RSI | 47.43 |
| Earnings Date | Jul 28, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial StatementsNews
GSK wins EU approval for drug combos containing blood cancer drug Blenrep
GSK's blood cancer drug gets EU approval for multiple myeloma
British drugmaker GSK said on Thursday the European Union has approved the company's blood cancer drug Blenrep for the treatment of relapsed or refractory multiple myeloma.
Companies Reporting: GSK, Shell, IAG
GSK, Shell and IAG are amongst the FTSE 350 and other companies reporting earnings for the week of 28 July
GSK's Blood Cancer Drug Review Extended As FDA Seeks More Data
The US Food and Drug Administration (FDA) on Wednesday extended the review period for the Biologics License Application (BLA) for GSK plc’s (NYSE: GSK) Blenrep combinations for relapsed or refractory...
GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults.
GSK gets extended review for blood cancer drug in U.S. despite negative AdCom vote
US FDA extends review of GSK's blood cancer drug
The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, the company said on Wednesday.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Daniell...
European Stocks Post Small Weekly Drop; GSK Weighs on Healthcare
European stocks ended the week with a small decline, as GSK Plc’s shares weighed on the healthcare sector on a busy earnings day.
Global Stocks Recap: Alibaba, Saab, Burberry, GSK
GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt
The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.
GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning
FDA panel rejects GSK's Blenrep combo due to ... Full story available on Benzinga.com
GSK Blindsided as Blenrep Stumbles Again in the US, Shares Dive
GSK shares sink after FDA panel rejects Blenrep cancer drug, raising doubts over turnaround strategy. The post GSK Blindsided as Blenrep Stumbles Again in the US, Shares Dive appeared first on Investo...
FTSE 100 Nears Record, GSK Slumps on FDA Setback
FTSE 100 nears record high as dealmaking cheers London, GSK slides on FDA Blenrep blow. The post FTSE 100 Nears Record, GSK Slumps on FDA Setback appeared first on Investomania .
GSK shares fall after blood cancer drug likely headed for U.S. rejection
GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over eye-related side effects.
FDA Committee Votes Against GSK Blood Cancer Drug Blenrep
The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or refractory multiple myeloma who have previously received at least one line of therap...
GSK's Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
Despite new market entrants in the form of Gilead's Livdelzi and Ipsen's Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an exis...
FDA advisers vote against combination therapies of GSK's blood cancer drug
The U.S. Food and Drug Administration's panel of independent advisers voted on Thursday against approval of GSK's blood cancer drug Blenrep for use in combination with other treatments.
GSK wins FDA nod for new shingles vaccine format
US FDA approves pre-filled version of GSK's shingles vaccine
The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix, providing patients a more convenient option to receive the shot, the company...
US FDA Approves GSK's SHINGRIX in a Prefilled Syringe Presentation
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe presentation of SHINGRIX (Zoster Vaccine...
FDA flags safety concerns related to GSK’s blood cancer drug ahead of AdCom meeting
FDA staff raises eye damage concerns for GSK's blood cancer drug
The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in ...
GSK’s RSV vaccine to be reviewed by FDA for expanded use
GSK seeks FDA nod for expanded use of RSV vaccine in adults
British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the use of its respiratory syncytial virus (RSV) vaccine to adults under the age...